ICD enhances anti-tumor immunity by promoting the maturation and activation of dendritic cells, which then present TAAs to T-cells. This presentation leads to the activation of cytotoxic T lymphocytes (CTLs), which can specifically target and destroy cancer cells. Furthermore, the release of DAMPs and cytokines creates a pro-inflammatory environment that supports the recruitment and activation of additional immune cells, amplifying the anti-tumor response.
